Online food allergy treatment: what can be remote, and what cannot
A practical guide to the clinician-led food SLIT pathway, from diagnosis and prescription to follow-up and supervised clinic challenges.
Curex offers physician-supervised sublingual drops for diagnosed IgE-mediated food allergy, with intake, prescription management and follow-up through telemedicine. Eligibility is individual; new or uncertain food allergy, anaphylaxis history and uncontrolled asthma need an in-person allergist assessment first. Food challenges must be performed in an equipped clinic, never at home. Do not introduce or reintroduce an allergic food to test progress. Peanut-SLIT trials support discussing this approach, but they do not establish Curex food-program outcomes, and Curex’s environmental-allergy cohort is not food-allergy evidence. Compounded food drops are not FDA-approved.
· Last verified: October 5, 2026
What online care can do
Online food allergy treatment is a care pathway, not a home food challenge
Online care can make specialist conversations, prescription management and follow-up easier to access. It cannot turn a suspected food allergy into a confirmed diagnosis by questionnaire, or make an allergic food safe to try at home. The useful question is not whether every appointment can be virtual; it is which parts of your care can be remote while the necessary in-person safeguards remain in place.
Curex offers physician-supervised sublingual immunotherapy (SLIT) for IgE-mediated food allergy: prescription allergen drops administered under the tongue, rather than a food eaten as an oral immunotherapy dose. The company describes a program for patients from age 2, with physicians trained in food allergy and pediatrics supervising by telemedicine. Its food treatment page describes the service. Eligibility still depends on the individual physician's assessment; an advertised age or food list is not clearance to start.
The treatment goal is to increase the amount of a food a patient can tolerate, with a supervised food challenge used when appropriate to assess progress. Curex describes eventual clearance for small amounts as a goal, not an outcome every patient achieves. Until your treating allergist specifically changes your plan after an in-person assessment, keep avoiding the diagnosed allergen and carrying prescribed epinephrine. Do not introduce, reintroduce or increase an allergic food at home to see whether the drops are working.
Before enrollment: establish what you are actually treating
The American College of Allergy, Asthma and Immunology's food allergy guide explains that diagnosis combines the reaction history with selected tests. A positive food-specific IgE result indicates sensitization; it does not by itself prove that eating the food causes allergy.
- Bring a reaction timeline. Record the food, approximate amount, time until symptoms, symptoms involved, treatment used and any emergency visit. Include foods you currently eat without symptoms, rather than assuming every positive result requires treatment or avoidance.
- Share existing records. Provide previous IgE results, skin tests, food challenge reports, emergency records and your current action plan. Curex accepts previous test results for review; the physician decides whether they are sufficient or whether additional targeted testing is needed.
- Clarify the diagnosis. IgE-mediated food allergy is not the same as lactose intolerance, celiac disease, non-IgE-mediated gastrointestinal disease or a general food sensitivity. Those conditions require their own evaluation and should not be treated as interchangeable indications for food SLIT.
- Keep the assessment targeted. Ask which foods should be tested based on your history. Broad panels can produce results that are difficult to interpret and lead to unnecessary restriction. Do not remove tolerated foods or deliberately eat a suspected allergen solely on the basis of an online test result.
Who needs in-person evaluation first?
A new or uncertain food allergy needs an in-person allergist assessment before a home treatment plan begins. The same applies to a history of anaphylaxis, severe or uncontrolled asthma, or suspected drug allergy. Remote intake can help collect information and arrange next steps, but it is not a substitute for examination or the facilities needed to manage a serious reaction.
Children need an age-appropriate assessment, a caregiver able to follow the written plan and coordinated school or childcare precautions. Being old enough for the advertised program is not sufficient. Young children, people who are pregnant or planning pregnancy, and anyone with important additional medical conditions need an individualized discussion of whether treatment should start, continue or be deferred. Tell the physician about swallowing problems, persistent gastrointestinal symptoms and all medications.
In-person evaluation does not necessarily exclude later remote follow-up. It establishes the diagnosis, risk profile and responsibilities before a prescription becomes a daily routine at home. If a necessary local assessment or challenge cannot be arranged, that is a care-access problem to resolve with the clinician—not a reason to attempt the procedure yourself.
The Curex process: what happens online and what does not
Curex describes intake, a care-manager onboarding call, physician consultation, specialty-pharmacy fulfillment and ongoing online supervision. The steps below explain the practical decisions to settle along that path; they are not dosing instructions.
| Stage | Remote component | Safety or access question to resolve |
|---|---|---|
| Intake and records | Complete the medical history and provide prior diagnosis, reactions, tests and medications. | Is an in-person evaluation required before prescribing? Who will arrange it? |
| Testing if needed | Curex supports local lab draws, an at-home phlebotomist or self-collection, with a physician choosing the appropriate tests. | Will this collection method answer the clinical question, and are skin testing or other investigations also needed? |
| Physician consultation | Review the history and results by video or secure text and discuss a proposed prescription. | Which foods, treatment goals and risks apply to this patient? Is food SLIT an appropriate option? |
| Treatment initiation | A specialty pharmacy prepares and ships the prescribed drops when treatment is approved. | Where must initiation or dose changes take place, and what training and emergency preparation are required? Do not assume shipping equals permission to start. |
| Ongoing follow-up | Care managers and physicians monitor progress and adjust the plan online. | When should dosing be held, and how are reactions, missed doses and out-of-hours concerns handled? |
| Assessing food tolerance | The remote team can review records and discuss whether a food challenge is appropriate. | A food challenge belongs in a suitably equipped clinic with an experienced allergist, never at home or by video alone. |
Daily treatment, reactions and the emergency boundary
Follow the prescription and written instructions specific to your formulation. Food SLIT is administered under the tongue; it is not interchangeable with oral immunotherapy, ordinary food, or an environmental allergy prescription. Do not make your own extracts, borrow someone else’s drops, change the schedule, catch up after missed doses or escalate a dose without the prescriber’s direction.
Mouth or throat itching was commonly reported in the peanut-SLIT studies below. That does not mean every symptom is harmless. Before the first dose, obtain a written plan explaining which symptoms require holding treatment, contacting the team or emergency action. Report reactions and persistent symptoms. If illness, asthma symptoms, a treatment interruption or a new medication changes your situation, ask the prescriber how to proceed rather than guessing.
Online messaging is not emergency care. Trouble breathing, throat swelling, faintness or other symptoms covered by your anaphylaxis action plan require immediate action: use prescribed epinephrine as directed and call 911. Do not wait for a portal reply or use antihistamines as a substitute for epinephrine. The ACAAI food allergy guide explains why an action plan and ready access to epinephrine remain necessary.
What the primary food-SLIT studies actually show
These are peanut studies conducted in defined pediatric research populations, with protocol-specific treatment and supervised challenges. They support discussing peanut SLIT; they are not trials of the Curex food service, every food allergen, or a personalized multi-food formulation.
| Primary publication | Population and follow-up | Observed result and limitation |
|---|---|---|
| Kim et al., 2019 (PMID 31493887) | 48 peanut-allergic children aged 1–11; extended treatment for up to 5 years; 37 completed 3–5 years. | 32/48 (67%) consumed at least 750 mg peanut protein at challenge; 12/48 (25%) passed the 5,000 mg challenge. Side effects occurred with 4.8% of doses; no epinephrine was administered. These are research outcomes, not permission to eat peanut at home. |
| Kim et al., 2023 (PMID 36828080) | Open-label prospective study of 54 children aged 1–11; 47 completed treatment and the 48-month challenge. | 33/47 completers (70.2%) achieved a successfully consumed dose of at least 800 mg peanut protein; 17/47 (36%) reached 5,000 mg. These percentages use the completer denominator, not all 54 enrolled children. The median reaction rate per dose was 0.5%, with no dosing symptoms requiring epinephrine. Without a placebo group, this study does not establish a comparative service success rate. |
| Kim et al., 2024 (PMID 37815782) | 50 children aged 1–4 randomized equally to peanut SLIT or placebo; 36 months of treatment. | 60% of the active group versus 0% of placebo passed the month-36 challenge; 48% versus 0% demonstrated remission after 3 months off treatment. The limited off-treatment period does not demonstrate permanent tolerance. |
Amounts are study challenge endpoints, not a home dosing or food-introduction guide. Results depend on age, allergen, selection, protocol, follow-up and the definition of the endpoint.
Keep protocol descriptions and Curex outcomes separate
Allergychoices has an existing food allergy protocol page describing individualized sublingual treatment under the La Crosse Method Protocol, with goals that vary by patient. It is a useful factual source for what that protocol describes. It is not an independent endorsement of Curex, a randomized study, or proof that another program uses the same formulation or achieves the same results. Its general discussion of positive tests must not replace clinical diagnosis.
Published pediatric peanut trials cannot establish a Curex food-program graduation rate, prove superiority over clinic treatment or supply success rates for milk, egg, shellfish or every other food. Ask the treating clinician what evidence exists for your particular allergen, age, formulation and intended outcome. A service can offer a treatment for a food for which the direct clinical evidence is much more limited than for peanut.
Curex’s 2026 study, PMID 42358593, is a retrospective environmental-allergy SLIT cohort of 2,897 adults with at least 12 months of follow-up. It is not a food allergy study. It cannot establish food challenge outcomes, food desensitization or the safety of food SLIT in children. Its observational design, self-reported outcomes and selected follow-up population also prevent treating it as comparative evidence.
Trade fewer routine trips for a clear, sustainable care plan
- Travel and scheduling.Online consultations and shipped prescriptions can reduce routine travel for families who live far from specialty care. The daily treatment commitment and needed local clinical services remain.
- Continuity.A named physician and care team can review symptoms, adherence and questions over time. Confirm how care continues during travel or a move, and which state licensing rules apply.
- Planning around real life.Discuss caregiver availability, school plans, refills, storage instructions and the cost of a prolonged course before starting. Convenience helps only if the plan can actually be followed.
- Observed procedures.A clinic can examine the patient, perform appropriate testing and conduct a supervised oral food challenge with emergency medication and equipment on site.
- Direct escalation support.Clinic-based immunotherapy programs can observe selected initiation or escalation steps and respond immediately to reactions. Ask about clinic options if your goals or risks require that setting.
- Complex-case evaluation.Uncertain diagnoses, anaphylaxis, uncontrolled asthma and other complicating conditions need more than a shipment and an online conversation.
Questions to ask before paying for an online food program
- Who is responsible for my clinical care? Get the name of the prescribing physician, the follow-up arrangements and the escalation route when the care manager cannot answer a medical question.
- What exactly is the goal? Separate a higher reaction threshold while dosing from remission after stopping, and both from clearance to eat a specified amount. Ask how the goal will be assessed and what happens if it is not reached.
- Where will the in-person parts happen? Identify a local clinician or challenge center, referral requirements, records transfer and who pays. Do not enroll on the assumption that a remote provider can perform a food challenge.
- What does the written safety plan say? Confirm epinephrine access, caregiver training, treatment-hold rules, follow-up after a reaction and the limits of after-hours support. Obtain those answers before initiation.
- What is the full cost and commitment? Request the food-program price rather than an environmental-plan starting price, plus testing, visits, challenge fees and prescriptions. Curex accepts insurance for testing and consultations, but payment depends on benefits. Ask about self-pay charges, refill timing and any balance owed for treatment already shipped if you cancel.
Regulatory status and your next step
Compounded food allergy drops are not FDA-approved, and the FDA has not evaluated an individual compounded formulation for safety and effectiveness. Approval of an allergenic extract for another use does not approve the sublingual route, a mixture or a food-treatment claim. The FDA's March 23, 2021 untitled letter to Curex addresses the drops and mixtures marketed at that time. See the Curex FDA correspondence record for the documents; the existence of a response is not FDA approval.
If you have an established diagnosis and want to understand whether remote follow-up fits, use the Curex food treatment page to request an assessment and bring the questions above. If the diagnosis or risk is uncertain, begin with an in-person allergist. For a broader comparison of treatment approaches rather than access and process, see food allergy treatment options.
❓Frequently Asked Questions
No. A positive food-specific IgE test can indicate sensitization without a clinical allergy. An allergist interprets the test alongside the reaction history and decides whether examination, skin testing or an oral food challenge is needed. New or uncertain food allergy should be assessed in person before home treatment begins.
Curex describes food SLIT for patients from age 2 with physician supervision by telemedicine. That is an advertised program age, not a guarantee of eligibility. A child needs an age-appropriate assessment, a capable caregiver and an emergency plan; young children or higher-risk cases need in-person evaluation before treatment.
Do not introduce, reintroduce or increase an allergic food at home to test the treatment. Continue the avoidance plan until your treating allergist changes it. A food challenge must occur under experienced medical supervision in a suitably equipped clinic, not at home or over a video call.
No. They studied defined pediatric peanut-allergy populations and research protocols, not the Curex service. Results cannot supply a Curex graduation rate or prove outcomes for every food or multi-food formulation. Curex’s 2,897-adult environmental-SLIT cohort also does not establish food outcomes.
No. Keep prescribed epinephrine available and follow your written action plan. Suspected anaphylaxis needs immediate epinephrine as directed and emergency services, not a message to the care team. Telemedicine follow-up is not emergency treatment.
Confirm diagnosis and eligibility, the named prescriber, initiation safeguards, treatment-hold instructions, follow-up access, and where in-person assessments and challenges will happen. Request a food-program cost estimate including testing, consultations, challenges and prescriptions. Compounded food drops are not FDA-approved; ask about evidence for your specific food and treatment goal.
General information, not individualized medical advice. Your treating clinician decides eligibility, treatment and dosing. For trouble breathing, throat swelling, faintness or a suspected severe allergic reaction, follow your prescribed emergency plan and call 911.
Sources
Written by Curex editorial team. Medical review has not been recorded.
- Curex supplied company source of truth: About Us — Curex, September 29, 2026 (editorial document)
- Curex food allergy treatment service, checked October 5, 2026
- ACAAI: food allergy diagnosis, clinical challenges and emergency management
- Kim et al., 2019: extended peanut SLIT in children (PMID 31493887)
- Kim et al., 2023: open-label pediatric peanut SLIT (PMID 36828080)
- Kim et al., 2024: randomized peanut SLIT trial in young children (PMID 37815782)
- Allergychoices: existing food allergy protocol description
- Curex environmental SLIT cohort; not food outcome evidence (PMID 42358593)
- FDA: March 23, 2021 untitled letter to Curex